Sentences with phrase «cytokine release syndrome»

CAR - T, though, is also associated with severe and potentially deadly side effects, including lethal instances of cytokine release syndrome with some patients dying from brain swelling in separate studies from the Novartis drug.
But while the technology itself is undeniably exciting, some companies, like Juno Therapeutics, have been struggling with the reality of dangerous side effects including cytokine release syndrome and brain swelling during trials.
CAR - T approaches involve reengineering T - cells to find and destroy cancer cells, but that process can cause cytokine release syndrome (CRS), a life - threatening immune response NantKwest hopes to sidestep.
All 10 patients who received the CTL119 cells experienced mild cytokine release syndrome (CRS), a known potentially lethal type of toxicity, within a few days after receiving their infusions; however, none required treatment with tocilizumab, an immunosuppressant drug that blocks the effects of the inflammatory cytokine IL - 6.
She battled what is known as cytokine release syndrome and neurological side effects, both common to CAR T - cell therapy, but quickly recovered.
In ZUMA - 1, 12 % of the patients had a grade 3 or higher cytokine release syndrome and that is essentially a patient requiring mechanical ventilation or needing treatment with a high - dose vasopressor.
Unfortunately, those patients may be unlikely to make it through the 17 days we need to manufacture the CAR T cells, and it is less likely that they will be able to tolerate the severe cytokine release syndrome or get through the other acute toxicities of therapy.
One patient had a myocardial infarction while suffering from cytokine release syndrome.
Cytokine release syndrome occurs when many cytokines get released into the serum upon CAR T - cell injection; patients can get high fevers and sometimes hypertension, and occasionally there is a need for mechanical ventilation or administration of vasopressors, but that is rare.
Toxicity is a significant concern with CAR T - cell therapies, since they have the capacity to elicit not only expected serious adverse events but also unexpected ones, including cytokine release syndrome (CRS), neurologic toxicity, «on target / off tumor» recognition, and anaphylaxis.
More than half (58 %) of treated patients in JULIET experienced cytokine release syndrome, which was a grade 3/4 event in about one - quarter of the patients.
After receiving the engineered cells, she experienced no fevers or other signs of cytokine release syndrome (CRS), a condition that has been observed in other patients undergoing CTL019.
«T - cell receptor therapy achieves encouraging clinical responses in multiple myeloma: NY - ESO T cell receptor therapy found to be safe, with no cytokine release syndrome cases.»
What's more, none of the patients experienced macrophage activate syndrome or cytokine release syndrome, an infusion reaction observed in other gene therapy trials characterized by fever, nausea, chills, hypotension or a rash.
All patients who received the CTL019 «hunter» cells experienced a cytokine release syndrome (CRS) within a few days after receiving their infusions — a key indicator that the engineered cells have begun proliferating and killing tumor cells in the body.
All six had cytokine release syndrome (CRS), from which they recovered after treatment with tocilizumab, an immunosuppressant drug that blocks the effects of the inflammatory cytokine IL - 6.
The two toxicities that we primarily see related to CAR T cells are cytokine release syndrome and CAR T - cell — related encephalopathy or neurologic events.
a b c d e f g h i j k l m n o p q r s t u v w x y z